Retatrutide Underdelivers, Novo Sues Lilly, and GSK Wins a Fast Lung Cancer Approval – This Week in Biotech #110
Lilly's triple agonist misses on cardiovascular outcomes, Novo Nordisk takes Lilly to court over "deceptively false" ads, and Trump threatens 200% generic drug tariffs (July 17–23, 2026).
Welcome back to This Week in Biotech by Biotech Blueprint, edition 110, covering biotech and pharma news from July 17 to July 23, 2026.
Solving the drug discovery crisis
More for everyone: how democratized tools can accelerate rare disease research.
🎙️ Biotech Blueprint brings you weekly video updates on the latest biotech and pharma news, plus in-depth podcast interviews with industry leaders. You can find us on YouTube, Spotify, and Apple Podcasts. If you want to be featured on our podcast, get in touch.
🌐 For consulting inquiries, please email us or visit BiotechBlueprintConsulting.com.
👥 If you haven’t already, please connect with me or follow me on LinkedIn.
🛒 Check out our newly launched MERCH STORE.
VIDEO SUMMARY
THIS WEEK’S KEY TAKEAWAYS 🔑
Another update in the GLP-1 world this week. For two years the only question that moved stocks was how much weight a drug takes off. Lilly’s retatrutide, the most powerful weight loss molecule in development, answered that question again with two more Phase 3 wins, and the market barely cared. What the market cared about was the two harder questions that came with the data. Does the weight loss protect the heart, and did the drug hold its own prior ceiling? Both answers were underwhelming. Peak weight loss came in around 21% to 23%, below the 28.3% retatrutide posted in TRIUMPH-1, and the trial specifically run in people with cardiovascular disease couldn’t show the drug reduced heart attacks, strokes, or cardiovascular death. The regulatory filing slipped to Q1 2027. Efficacy has a visible ceiling now, and the next front is outcomes data.
That front is also a courtroom. In the same week retatrutide disappointed, Novo Nordisk sued Lilly over what it calls “maliciously and deceptively false” advertising comparing the highest doses of the two companies’ drugs. The two players who own the obesity market aren’t just competing on weight percentages and payer coverage anymore. They’re competing on what each is allowed to say about the other. When rivals move from trial design to trademark law, it usually means the clinical differentiation has narrowed enough that how you talk about the drug matters.
M&A this week kept validating on the science while raising the price question. GSK’s $10.6 billion purchase of Nuvalent, closed only a week earlier, already produced an FDA approval two months ahead of schedule for Jideytro in ROS1-positive lung cancer, GSK’s first lung cancer drug ever. In the same news cycle, the post-mortem on Vertex’s $10 billion Crinetics deal revealed that Vertex was the sole bidder and paid the second-highest premium of biotech’s banner M&A year. It was essentially bidding against itself.
Two policy stories are worth mentioning. President Trump threatened tariffs of up to 200% on generic drugs not manufactured in the United States, the first time copycat medicines specifically have been targeted, which matters far more to drug supply than the branded pharma levies did. Sartorius became the first life science company to quantify the other side of the tariff mess, cutting revenue by 26 million euros to refund customers after the Supreme Court blocked some of the earlier levies. Meanwhile Merck’s Rob Davis warned Congress that cutting off China dealmaking would cost the US its status as the world’s biotech leader. So now the biggest pharma CEOs are publicly arguing against restrictions on China deals while their own companies keep signing them.
BIOTECH/PHARMA NEWS 🧬
🔹 Novo Nordisk took Lilly to court over advertising that compares the highest doses of Zepbound and Wegovy and claims Lilly’s products are broadly superior. Novo calls the campaign “maliciously and deceptively false” and filed after a cease and desist request went nowhere. Lilly countered that its campaign is “truthful.” The lawsuit is the clearest sign yet that better clinical data is not enough to win share anymore in obesity. Lilly’s tirzepatide has generally shown deeper weight loss than semaglutide in head to head reads, which is exactly why Novo is contesting how that comparison is framed to prescribers and patients. As both franchises reach tens of $billions in revenue and the pipeline gap narrows, how each company markets against the other is now worth taking to court. Worth watching whether a court is willing to police direct drug versus drug advertising claims, which would set a precedent for every crowded category behind obesity.
🔹 The FDA approved GSK’s Jideytro (zidesamtinib) for previously treated ROS1-positive metastatic non-small cell lung cancer, GSK’s first lung cancer approval and the payoff on its largest acquisition in eight years. The clearance landed ahead of a September 18 decision date, helped by breakthrough therapy and orphan drug designations. ROS1 rearrangements appear in roughly 2% of non-small cell lung cancer, a small but well defined niche where selectivity, resistance-mutation coverage, and control of brain metastases decide the winner against existing drugs. GSK essentially bought a derisked, nearly approval asset and got revenue faster than its own model assumed, with a second Nuvalent drug, neladalkib, still under FDA review. This is the cleaner half of the M&A validation story this week. Pay up for a specific molecule near the finish line and the timeline can surprise to the upside.
🔹 The regulatory filing behind Vertex’s $10B Crinetics acquisition showed Vertex was the only company at the table and still paid the second highest premium in a year full of premiums. Analysts expect the disclosure to reignite the concern that Vertex overpaid for its largest ever deal, an endocrine pivot beyond cystic fibrosis anchored by Palsonify in acromegaly and atumelnant in late stage adrenal disease. The detail that matters is the absence of a competing bid. A 100%+ premium is easier to defend when two strategics are fighting over an asset, but it is much harder when the acquirer set the price against no one. The clinical thesis doesn’t change here, since Crinetics has a differentiated oral endocrine portfolio, but it sharpens the question of what disciplined dealmaking looks like when capital is cheap and the IPO window is wide open.
🔹Two policy stories worth mentioning this week. President Trump pledged tariffs of up to 200% on generic drugs not made in the United States, the first time generics specifically have been targeted. That is a bigger deal than the branded pharma tariffs that had limited revenue impact, because generics are where supply is thinnest, margins are lowest, and shortages are already common. A punitive import levy on copycat medicines could disrupt the drugs most Americans actually take. Separately, Sartorius cut its revenue guidance by 26M euros to refund customers for tariff surcharges it had passed on earlier in the year, after the Supreme Court blocked some of those tariffs. It is the first company to publicly quantify the financial cost of the on-again, off-again tariff policy. And Merck CEO Rob Davis warned Congress that restricting US-China dealmaking would cost the country its biotech leadership position, given how many pipeline drugs now come from Chinese licensing. Trade and China policy are quickly becoming things pharma companies have to actively plan around.
🔹 Repligen agreed to acquire cell processing supplier BioLife Solutions for roughly $1.5B, about 36% of it in stock. The interesting angle is what Repligen is buying. BioLife supplies reagents, media, and cold chain equipment to cell and gene therapy developers. So this is one tools company buying another tools company, which is essentially a bet that cell and gene therapy manufacturing volume keeps growing overall, regardless of which specific drugs succeed. BeOne (formerly BeiGene) also announced a $300M domestic manufacturing expansion the same day. Both deals show that some of the biggest checks in biotech right now are going to infrastructure.
🔹 Lilly’s retatrutide, a triple agonist that hits the GLP-1, GIP, and glucagon receptors, met the primary endpoints of both Phase 3 trials but on terms that cooled the enthusiasm. In TRIUMPH-2, the type 2 diabetes cohort, top-dose patients lost about 21% of body weight at 80 weeks. In TRIUMPH-3, run in people with established cardiovascular disease, weight loss reached roughly 22.6% to 23%. Both are strong absolute numbers and both fall short of the 28.3% retatrutide posted in TRIUMPH-1 in people without diabetes, which is the expected pattern since diabetes and cardiovascular populations typically lose less. The disappointment is the heart data. TRIUMPH-3 recorded 27 major adverse cardiovascular events on retatrutide versus 23 on placebo for the three point measure of cardiovascular death, heart attack, and stroke. So the drug didn’t demonstrate it lowers cardiovascular risk. A broader five point measure that adds all cause death and heart failure numerically favored the drug, but the sample is too small and the follow up too short to draw a clean conclusion. Lilly now plans to file with the FDA in Q1 2027, delayed for manufacturing and quality data. Retatrutide will very likely be the most powerful weight- oss drug on the market, but the industry’s next differentiator, proving the weight loss translates into fewer heart attacks and strokes, remains unclaimed. Novo’s semaglutide already carries a cardiovascular benefit label, which is precisely the ground the two companies are now fighting over in court.
🔹 Arrowhead’s RNA-interference drug plozasiran hit strong numbers in two late-stage trials in severe hypertriglyceridemia, a much larger patient population than the ultra rare familial chylomicronemia syndrome where the drug is first headed. Plozasiran cut triglycerides by a median 79% in one trial and 81% in the other at one year, versus roughly 27% in the placebo arms. A pooled analysis showed a 78% reduction in acute pancreatitis events, which is the complication that kills people with severe hypertriglyceridemia. Safety was clean, with no meaningful liver enzyme or platelet changes. The biggest practical advantage is dosing. Plozasiran is a subcutaneous injection once every three months. Ionis’s Tryngolza requires monthly injections. Arrowhead plans to file to add severe hypertriglyceridemia to the Redemplo label before the end of 2026.
🔹 Summit released longer follow up on its PD-1/VEGF bispecific ivonescimab in an effort to answer the skeptics who have questioned whether the striking Asian trial results hold up in Western patients. The updated cut of the global Phase 3 offered two year survival data with a favorable read, but the context investors most want is still missing: the direct, adequately powered comparison of benefit between Asian and Western populations. The stock has traded on this exact uncertainty all year, including a pulled secondary offering in June. Ivonescimab remains the most important test of whether Western regulators and prescribers will accept a China-originated oncology drug on data largely generated abroad, and this readout narrows but doesn’t close the gap. It keeps the idea alive that the bispecific works across populations without yet proving it.
Have a great rest of your week and thanks for reading Biotech Blueprint!
DISCLAIMER: This publication is for informational and educational purposes only and does not constitute investment, legal, medical, or tax advice, a solicitation, or an offer to buy/sell any security. Information is believed reliable but no warranty is made as to accuracy or completeness; views may change without notice. Do your own research and consult qualified professionals.
DISCLOSURE & CONFLICTS: The author may hold positions in securities mentioned and may change positions at any time without notice. No compensation is received from companies mentioned, and there are no known material business relationships unless explicitly stated. Content may reference clinical data and regulatory events; always consult primary sources and a licensed clinician for medical decisions. Past performance is not indicative of future results.
LIABILITY: Use of this content is at your own risk. The author assumes no responsibility for any losses arising from reliance on this material.
Image source: The Motley Fool.